Related Experiment Video
Updated: Nov 25, 2025
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.5K
A TP53-based immune prognostic model for muscle-invasive bladder cancer
Hongyan Li1, Huayi Lu2, Wanli Cui1
1Jilin Key Laboratory of Urologic Oncology, Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China.
Aging
|December 16, 2020
Summary
This study links TP53 mutations to the immune microenvironment in muscle-invasive bladder cancer (MIBC). A new immune prognostic model (IPM) predicts survival, identifying high-risk patients with distinct immune cell profiles and higher immune checkpoint gene expression.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Muscle-invasive bladder cancer (MIBC) presents limited treatment options and high recurrence rates.
- TP53 mutation status is a critical factor influencing MIBC progression and patient prognosis.
- Understanding the interplay between TP53 mutations and the tumor immune microenvironment is crucial for improving outcomes.
Purpose of the Study:
- To investigate the association between TP53 mutations and the immunophenotype in muscle-invasive bladder cancer (MIBC).
- To develop and validate an immune prognostic model (IPM) for MIBC patients based on TP53 mutation status.
- To assess the clinical utility of the IPM in predicting patient survival.
Main Methods:
- Utilized The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases for gene expression data.
- Performed differential gene expression analysis between TP53-mutated and wild-type MIBC cohorts.
- Employed the CIBERSORT algorithm to quantify immune cell proportions and developed an IPM using univariate and LASSO Cox regression analyses.
Main Results:
- An immune prognostic model (IPM) was established and validated, classifying MIBC patients into low and high-risk subgroups.
- High-risk patients exhibited increased M1 macrophages but decreased regulatory T cells (Tregs) and activated dendritic cells.
- Elevated expression of immune checkpoint genes (PD1, CTLA4, LAG3, HAVCR2, TIGIT) was observed in high-risk MIBC patients.
- The IPM demonstrated superior survival prediction compared to conventional clinical characteristics.
Conclusions:
- The developed IPM holds significant prognostic value for muscle-invasive bladder cancer patients.
- The study elucidates the immune landscape within the MIBC microenvironment in relation to TP53 mutation status.
- This research provides a foundation for targeted immunotherapies and improved clinical management of MIBC.
